Moody's
INVESTORS SERVICE

Rating Action: Moody's assigns Aa3 to Advocate Aurora Health's Ser. 2019; outlook revised to positive

29 Oct 2019

New York, October 29, 2019 -- Moody's Investors Service has assigned a Aa3 rating to Advocate Aurora Health's proposed Taxable Bonds, Series 2019 ($363.2 million). The bonds are expected to be issued as fixed rate with a bullet maturity in 2049. Concurrently, the outstanding ratings on Advocate Aurora Health's obligations, which include legacy borrower Aurora Health Care, Inc., WI, have been affirmed at Aa3, Aa3/VMIG 1 and Aa3/P-1. The outlook has been revised to positive from stable. These actions affect approximately $2.3 billion of debt

RATINGS RATIONALE

Affirmation and assignment of the Aa3 reflect Moody's expectation that Advocate Aurora Health (AAH) will continue to benefit from size and scale as a market leader within two relatively large service areas and will be able to expand and leverage its experience in value based care across its regions. Moody's expects AAH will be able to integrate, as it has thus far, its two legacy systems without major disruption. Also, the system will be better positioned to realize further synergies because of its more streamlined management structure and a common IT platform. Additionally, Moody's expects AAH will maintain low leverage, a favorable liquidity position, and healthy margins (absent non-recurring expenses), as seen over the last 18 months. Offsets include fierce competition in rapidly consolidating markets, pricing pressure and unfavorable payor mix shifts, particularly in the Illinois region, as well as elevated capital spend over the coming two years.

The VMIG 1 rating reflects the availability of bank standby bond purchase agreements for unremarketed tenders of variable rate bonds. The P-1 rating for bonds in the Windows mode reflects market access based on the system's ample liquidity and notice to pay unremarketed tenders.

RATING OUTLOOK

The revision of the outlook to positive from stable reflects Moody's expectation that over the next two years, AAH will continue to achieve normalized operating cash flow margins in the 9.5% to 10% range, aided by diversification of revenues and achievement of synergy targets. Moody's expects that this successful execution will continue to be supported by a more streamlined management structure. Likewise, Moody's expects cashflow growth will continue to result in incremental strengthening of balance sheet measures.

FACTORS THAT COULD LEAD TO AN UPGRADE

- Ability to see improvement in and sustain strengthening of balance sheet measures
- Able to sustain very good operating cash flow margins
- For the unenhanced short-term rating: Not applicable
- For the enhanced short-term rating: Not applicable

FACTORS THAT COULD LEAD TO A DOWNGRADE

- Meaningful liquidity decline
- Lower than expected operating cashflow margins
- Increased leverage resulting in notable impairment of debt metrics
- For the unenhanced short-term rating: downgrade by Moody's of AAH's long-term rating below A2
- For the enhanced short-term ratings: a downgrade by Moody's of the short-term Counterparty Risk Assessment of the Bank that provides the SBPA
LEGAL SECURITY

Under an Amended and Restated Master Trust Indenture, issued in 2018, security is a general, unsecured obligation of the obligated group. There is no additional indebtedness tests. The members of the obligated group under the Master Indenture are: Advocate Aurora Health, Inc., Advocate Health Care Network, Advocate Health and Hospitals Corporation, Advocate Sherman Hospital, Advocate North Side Health Network, Advocate Condell Medical Center, Aurora Health Care, Inc., Aurora Health Care Metro, Inc., Aurora Health Care Southern Lakes, Inc., Aurora Health Care Central, Inc. d/b/a Aurora Sheboygan Memorial Medical Center, Aurora Medical Center of Washington County, Inc., Aurora Health Care North, Inc. d/b/a Aurora Medical Center Manitowoc County, Aurora Medical Center of Oshkosh, Inc., Aurora Medical Group, Inc., Aurora Medical Center Grafton LLC. The Amended and Restated MTI contains a substitution of notes provision.

USE OF PROCEEDS

Bond proceeds will be used to refund outstanding debt of AAH.

PROFILE

Advocate Aurora Health, Inc. (AAH; $12 billion revenue), provides a continuum of care through its 27 acute care hospitals, an integrated children's hospital and a psychiatric hospital, which in total have over 6,500 licensed beds, primary and specialty physician services with approximately 3,700 employed physicians, outpatient centers, physician office buildings, pharmacies, behavioral health care, rehabilitation, home health and hospice care in northern and central Illinois, eastern Wisconsin and the upper peninsula of Michigan.

METHODOLOGY

The principal methodology used in the long-term underlying ratings was Not-For-Profit Healthcare published in December 2018. The principal methodology used in the short-term underlying rating was US Bond Anticipation Notes and Related Instruments Methodology published in October 2019. The principal methodology used in the long-term enhanced ratings was Variable Rate Instruments Supported by Conditional Liquidity Facilities published in March 2017. Please see the Rating Methodologies page on www.moodys.com for a copy of these methodologies.

REGULATORY DISCLOSURES

For ratings issued on a program, series, category/class of debt or security this announcement provides certain regulatory disclosures in relation to each rating of a subsequently issued bond or note of the same series, category/class of debt, security or pursuant to a program for which the ratings are derived exclusively from existing ratings in accordance with Moody's rating practices. For ratings issued on a support provider, this announcement provides certain regulatory disclosures in relation to the credit rating action on the support provider and in relation to each particular credit rating action for securities that derive their credit ratings from the support provider's credit rating. For provisional ratings, this announcement provides certain regulatory disclosures in relation to the provisional rating assigned, and in relation to a definitive rating that may be assigned subsequent to the final issuance of the debt, in each case where the transaction structure and terms have not changed prior to the assignment of the definitive rating in a manner that would have affected the rating. For further information please see the ratings tab on the issuer/entity page for the respective issuer on www.moodys.com.

Regulatory disclosures contained in this press release apply to the credit rating and, if applicable, the related rating outlook or rating review.

Please see www.moodys.com for any updates on changes to the lead rating analyst and to the Moody’s legal entity that has issued the rating.

Please see the ratings tab on the issuer/entity page on www.moodys.com for additional regulatory disclosures for each credit rating.

Beth Wexler
Lead Analyst
PF Healthcare
Moody’s Investors Service, Inc.
7 World Trade Center
of Moody’s Group Japan G.K., which is wholly-owned by Moody’s Overseas Holdings Inc., a wholly-owned subsidiary of MCO. Moody’s SF Japan K.K. ("MSFJ") is a wholly-owned credit rating agency subsidiary of MJKK. MSFJ is not a Nationally Recognized Statistical Rating Organization ("NRSRO"). Therefore, credit ratings assigned by MSFJ are Non-NRSRO Credit Ratings. Non-NRSRO Credit Ratings are assigned by an entity that is not a NRSRO and, consequently, the rated obligation will not qualify for certain types of treatment under U.S. laws. MJKK and MSFJ are credit rating agencies registered with the Japan Financial Services Agency and their registration numbers are FSA Commissioner (Ratings) No. 2 and 3 respectively.

MJJK or MSFJ (as applicable) hereby disclose that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by MJKK or MSFJ (as applicable) have, prior to assignment of any rating, agreed to pay to MJKK or MSFJ (as applicable) for ratings opinions and services rendered by it fees ranging from JPY125,000 to approximately JPY250,000,000.

MJKK and MSFJ also maintain policies and procedures to address Japanese regulatory requirements.